Speaker Profile
M.D., Chief Executive Officer, BioAro
Biography
Dr. Anmol S. Kapoor is a cardiologist, entrepreneur, and founder of BioAro, a next-generation precision health company integrating genomics, multi-omics, and advanced AI to transform clinical care. Under his leadership, BioAro has built a global ecosystem spanning whole-genome and cancer sequencing, pharmacogenomics, microbiome testing, telomere biology, and longevity sciences.Driven to bridge the gaps of traditional medicine, Dr. Kapoor is advancing a prediction-, prevention-, and personalization-focused model that empowers clinicians across cardiology, oncology, dermatology, gastroenterology, gynecology, and longevity medicine.He also founded PanOmiQ, an AI-powered therapy-selection and multi-omics platform, and pioneered BioEMRBioELR, next-generation electronic record systems integrating AI into everyday practice. Through Kapoor Wealth Partners, he supports breakthrough ventures in medtech, biotech, digital health, and longevity.Internationally recognized in digital health and multi-omics innovation, Dr. Kapoor is shaping the global adoption of data-driven, patient-centered healthcare.
Talk
Genelio: Democratizing Access to Precision Medicine
Genelio is transforming precision medicine by making multiOmics intelligence accessible to everyone. Powered by AI and LLM-driven BioIntelligence, it turns complex multi-Omics data into simple, conversational insights which enables individuals, clinicians, and researchers to understand risks, optimize health, and make informed decisions without barriers to expertise.
Large-Scale Data Solutions Showcase:
BioAro Inc.
BioAro advances longevity through AI, LLM-powered BioIntelligence, and Axion hardware, integrating genomics, multi-omics lab testing, and real-time analysis. Its PanOmiQ platform unifies DNA, microbiome, and metabolic insights to deliver predictive, personalized, and proactive precision health.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Large Scale Data Solutions Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
